These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12947600)

  • 1. [Treating cognitive disorders in Alzheimer's disease: yes, but not only that].
    Forette F
    Presse Med; 2003 Jul; 32(24 Suppl):S3-4. PubMed ID: 12947600
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study.
    Canevelli M; Adali N; Kelaiditi E; Cantet C; Ousset PJ; Cesari M;
    Phytomedicine; 2014 May; 21(6):888-92. PubMed ID: 24548724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's drugs deliver fringe benefits. Cholinesterase inhibitors improve more than just memory.
    Auerbach SH
    Health News; 2003 Mar; 9(3):1-2. PubMed ID: 12703432
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
    Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH
    Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mild cognitive impairment and preclinical Alzheimer's disease.
    Morris JC
    Geriatrics; 2005 Jun; Suppl():9-14. PubMed ID: 16025770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy.
    Paterson RW; Abdi Z; Haines A; Schott JM
    Clin Neurol Neurosurg; 2016 May; 144():64-6. PubMed ID: 26989943
    [No Abstract]   [Full Text] [Related]  

  • 7. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
    Brousseau G; Rourke BP; Burke B
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
    Harry RD; Zakzanis KK
    Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical treatment of cognitive disorders in Alzheimer's disease.
    Senin U; Cherubini A; Palumbo B; Mecocci P
    Funct Neurol; 1997; 12(3-4):211-2. PubMed ID: 9218980
    [No Abstract]   [Full Text] [Related]  

  • 10. [The pharmacotherapy of the cognitive disorders in Alzheimer's disease. Guidelines for rational drug use--a review].
    Strnad J; Bahro M
    Dtsch Med Wochenschr; 2000 Jul; 125(27):835-9. PubMed ID: 10929539
    [No Abstract]   [Full Text] [Related]  

  • 11. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
    Doody RS
    J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cholinesterase inhibitor therapy for Alzheimer's disease: implications for long-term care.
    Brangman SA
    Am J Alzheimers Dis Other Demen; 2003; 18(2):79-84. PubMed ID: 12708222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study.
    Calabria M; Geroldi C; Lussignoli G; Sabbatini F; Zanetti O
    Arch Gerontol Geriatr; 2009; 49(1):e6-11. PubMed ID: 18768226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2007 Feb; 5(54):9-14. PubMed ID: 17261969
    [No Abstract]   [Full Text] [Related]  

  • 18. Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics.
    Rainer M; Mucke HA; Krüger-Rainer C; Kraxberger E; Haushofer M; Jellinger KA
    J Neural Transm (Vienna); 2001; 108(11):1327-33. PubMed ID: 11768631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Care of individuals with Alzheimer's disease in the new millennium.
    Souder E; Rapp CG; Davis GV; Beck C; Liem PH
    Medsurg Nurs; 2004 Feb; 13(1):22-31. PubMed ID: 15029928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metrifonate: update on a new antidementia agent.
    Ringman JM; Cummings JL
    J Clin Psychiatry; 1999 Nov; 60(11):776-82. PubMed ID: 10584768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.